Obesity Management

Full data from the SELECT trial offer insight into the 20% relative risk reduction associated with use of semaglutide 2.4 mg in patients with overweight or obesity and preexisting cardiovascular disease at AHA 2023.

In this episode, hosts discuss the FDA's approval of tirzeptiade (Zepbound) as an adjunct to lifestyle modification for the chronic weight management in people with overweight or obesity.

Announced on November 8, 2023, the approval of tirzepatide(Zepbound) was awarded to Eli Lilly and Company and represents the first chronic weight management approval for a dual GLP-1/GIP receptor agonist.

Check out perspective from a pair of ASN Kidney Week 2023 interviews with leading trialists discussing the evolution of cardiovascular-kidney-metabolic syndrome and how pharmacotherapy has propelled the growing recognition.

In our October 2023 endocrinology month in review, our editorial team highlights regulatory updates, pipeline news, and conference data capturing the attention of the field during the month.

In this episode, hosts discuss the results of SURMOUNT-3 and SURMOUNT-4 as well as how it might help inform use of tirzepatide if approved by the US Food and Drug Administration for chronic weight management.

The 15 mg dose of tirzepatide was the most efficacious GLP-1 agonist for obesity management in patients without diabetes in a systemic review of data from MEDLINE and Embase databases.

Presented at Obesity Week 2023, SURMOUNT-3 provides new insight into the effects of tirzepatide in patients with overweight or obesity.

Prespecified analysis of STEP-HFpEF trial shows semaglutide benefits consistent across ejection fraction spectrum, offering potential HFpEF management.

GLP-1 agonists for weight loss increased the risk of pancreatitis, gastroparesis, and bowel obstruction compared with the use of bupropion-naltrexone.

A network meta-analysis suggests tirzepatide may be more effective than semaglutide in reducing HbA1c and body weight in type 2 diabetes but may increase gastrointestinal adverse events, especially at higher doses.

Data from a 4-year trial of preschool-aged children offers new insight into the effects of initiating obesity management strategies among children in early life.

An analysis of CDC data from 1999 to 2020 offers clinicians a snapshot of overall, and race-specific, trends in obesity-related cardiovascular disease deaths since the turn of the century.

Less than 2 weeks after the release of their SELECT reaction podcast, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, sit down for a special edition episode of Diabetes Dialogue to discuss STEP-HFpEF data and the implications for semaglutide 2.4 mg.

Results of the STEP-HFpEF trial suggest use of semaglutide 2.4 mg (Wegovy) was associated with improvements in physical symptoms and functional status relative to placebo therapy in adults with HFpEF and obesity.

Using data and eligibility criteria from the STEP 1 trial, a California-based team estimates 93 million US adults met criteria for semaglutide 2.4 mg and use could prevent 1.5 million incident cardiovascular events over a 10-year period.

In this episode, hosts take time to break down the implications of two, potentially paradigm-shifting news in the announcement of the addition of bexagliflozin to the Cost Plus Drugs platform and topline data from the landmark SELECT trial.

In a recent Q&A, Michael Blaha, MD, discusses how he views the ideal role of cardiologists in the management of obesity and how this role could change based on the results of the SELECT trial.

Novo Nordisk has announced topline data from the SELECT trial, which suggest use of once-weekly semaglutide 2.4 mg was associated with a statistically significant 20% reduction in 3-point MACE among a cohort with overweight or obesity and established cardiovascular disease.

While tele-CBT did not lead to significant changes in short-term weight outcomes, it was effective in improving disordered eating behaviors and reducing psychological distress.

A cross-sectional analysis of more than 100 countries and regions revealed a statistically significant association between the prevalence of daily soft drink consumption and the prevalence of overweight and obesity.

On July 27, 2023, Eli Lilly and Company announced topline results of the SURMOUNT-3 and SURMOUNT-4 trials, with both trials achieving all primary endpoints of interest and full results scheduled to be presented later this year.

A new scientific statement indicates lifestyle interventions may change the trajectory of obesity-related cardiovascular risk from onset in childhood to manifestation in adulthood.

The BARI-OPTIMISE randomized clinical trial reports individuals with poor weight loss after metabolic surgery had significantly greater reductions in body weight after treatment with 3.0 mg liraglutide, compared with placebo.

With the popularity of the class skyrocketing, the American Society of Anesthesiologists has released new guidance urging patients to withhold GLP-1 receptor agonist use prior to elective surgeries or procedures based on potential risk of regurgitation and aspiration associated with delayed gastric emptying.